Xtant Medical extends deadline to terminate Surgalign asset purchase agreement to July 20, 2023

Xtant Medical Holdings, Inc.

First Amendment extends Xtant's termination right deadline from July 10 to July 20, 2023 for reviewing disclosure schedules.
Amends mutual release provisions in the original Asset Purchase Agreement to clarify scope.
Original deal: Xtant pays $5M cash for hardware/biologics assets of Surgalign in Chapter 11.
Xtant is stalking horse bidder; auction may result in higher or better offers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Xtant Medical Holdings, Inc. amended Asset Purchase Agreement with Surgalign Holdings, Inc. valued at $5 million in cash (effective 2023-07-10).

Action: amendment
Agreement: asset purchase
Counterparty: Surgalign Holdings, Inc.
Value: $5 million in cash
Effective: 2023-07-10

Exact text from the filing

On July 10, 2023, the Company and the Seller entered into a First Amendment to Asset Purchase Agreement (the “Amendment”).

View on SEC.gov

Browse all material agreements →

Xtant Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-024228

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.